NH lawmakers want antipsychotic sales probed; Sandoz recalls eye drug in Canada

> A group of New Hampshire legislators petitioned their attorney general to launch a criminal investigation of several drugmakers that market antipsychotic meds. Report

> Sandoz, the generics arm of Novartis, is recalling its Timolol prescription eyedrops in Canada because they may contain too much active ingredient. Report

> GlaxoSmithKline will pay its Relenza partner $19 million to settle a lawsuit in which Biota accused GSK of inadequately promoting and marketing  the drug. Report

> Amgen's Enbrel injected into the spine of 12 Alzheimer's patients produced rapid improvements in verbal fluency in an uncontrolled trial, researchers said. Report

> India's Dr. Reddy's Laboratories posted a 26 percent drop in first-quarter net profit, as higher costs and expenses offset a 25 percent rise in revenue. Report

> TheStreet's Adam Feuerstein rated Gilead Science's second quarter numbers "uninspiring," with strong top-line results and a disappointment in earnings. Report

> A drug once approved as an antihistamine in Russia improved thinking processes and ability to function in patients with Alzheimer's disease in a study conducted there. Report

> PTC Therapeutics has been on a roll over the last few months. But the biotech hit a loud bump when the New York Times featured the story of one mother's legal fight to gain access to PTC124 for her son, who suffers from Duchenne muscular dystrophy. Report

> Canada's MDS is slashing 210 jobs at its MDS Pharma Services and MDS Analytical Technologies divisions and is writing down the value of a Montreal facility. MDS report

> Interested in a government career devoted to drug development? Check out the FDA. The agency says it will launch a new, two-year fellowship program aimed at physicians, chemists and other pros who would like to come on board. FDA report

Emerging Drug Developer: VLST

And Finally... How, exactly, did Wal-Mart become the new FDA? Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.